Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
HL

NYSE · HLN

Haleon plc

Healthcare · Drug Manufacturers - Specialty & Generic

$8.66

Up+$0.09 (+1.05%)

Updated Oct 31, 2026, 5:00 PM

SID Score

5.5/10

Composite research score

Smart Money

56/100

Neutral

Market cap
43.5B
P/E ratio
21.41
Dividend yield
2.03%
52-week range
$8.38 – $11.28
Volume
32.53M
Avg. volume
11.03M

Price performance · HLN

HLN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

HLN closed at $8.66 after 21 trading sessions, down 1.59% for the selected period.

Last close
$8.66
Period change
-1.59%
Period low
$8.57
Period high
$10.37
Daily close
View OHLC price history
HLN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$8.665$8.785$8.61$8.6632.53M
Oct 29, 2026$8.55$8.75$8.38$8.5756.76M
Oct 28, 2026$10.00$10.1076$9.965$10.0022.19M
Oct 27, 2026$10.13$10.15$10.0601$10.0815.86M
Oct 26, 2026$10.23$10.32$10.19$10.2015.27M
Oct 23, 2026$10.30$10.335$10.22$10.2715.07M
Oct 22, 2026$10.13$10.395$10.12$10.3714.62M
Oct 21, 2026$10.105$10.145$10.02$10.0213.01M
Oct 20, 2026$10.16$10.25$10.115$10.1718.76M
Oct 19, 2026$10.06$10.19$10.05$10.1420.19M
Oct 16, 2026$9.98$10.135$9.9601$10.1318M
Oct 15, 2026$9.97$10.06$9.905$9.9418.33M
Oct 14, 2026$9.53$9.705$9.4904$9.6813.84M
Oct 13, 2026$9.555$9.59$9.42$9.4413.52M
Oct 12, 2026$9.35$9.51$9.33$9.5019.37M
Oct 9, 2026$9.27$9.32$9.235$9.3211.3M
Oct 8, 2026$9.10$9.26$9.08$9.2620.28M
Oct 7, 2026$9.13$9.155$9.01$9.0218.24M
Oct 6, 2026$8.95$8.955$8.825$8.8712.84M
Oct 5, 2026$8.84$8.88$8.79$8.8211.87M
Oct 2, 2026$8.79$8.81$8.71$8.8022.39M

Latest HLN news

The latest Smart Investors Daily articles mentioning HLN.

Stock researchCompany · Overview

HLN research

Overview

Company profile and research snapshot.

Company profile

Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$10.20
Implied upside
—
Analysts
5
HLN recent ratings
DateFirmRatingTarget
Jul 1, 2026DeutscheSell—
Jun 25, 2026JP Morgan CazenoveUnderweight—
May 5, 2026JefferiesBuy—
Apr 30, 2026Berenberg BankBuy—
Apr 30, 2026RBC Capital MarketsSector Perform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 19, 2026

Haleon Launches ‘Haleon Health House,’ a One-Day Interactive Wellness Pop-Up in Toronto

Limited-time experience invites Canadians to explore trusted health solutions, connect with experts and discover practical ways to support their wellbeing Haleon Canada invites Torontonians to experience the Haleon Health House Haleon Canada invites Torontonians to experience the Haleon Health House TORONTO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- On October 23, Haleon Canada is inviting Torontonians to step inside the “Haleon Health House,” a first-of-its-kind immersive experience designed to help pe

Yahoo · Oct 18, 2026

Will Headache Remedy Launch Change Haleon's (LSE:HLN) Narrative

Haleon announced Excedrin Rapid Relief, an aspirin free and caffeine free pain reliever with patented Fast Release Technology that is marketed alongside a nostalgic “My Little Headache” digital pet experience highlighting the need for quick headache relief. The My Little Headache campaign uses escalating digital pet chaos that only settles once the pet takes Rapid Relief, directly reinforcing the product’s 15 minute onset message and broad everyday pain positioning. We will examine how...

Yahoo · Oct 18, 2026

Haleon And 2 British AI Healthcare Stocks To Watch

America’s vast AI infrastructure build is starting to look more fragile, and that matters for UK investors watching where the real value sits in artificial intelligence. Hardware projects can stall when financing or public support weakens. Software that helps doctors work faster and make better calls in hospitals can keep scaling with fewer physical bottlenecks. This article highlights three UK listed AI driven healthcare stocks from our screener. The three stocks in this article are just a...

Yahoo · Oct 15, 2026

Is Haleon (LSE:HLN) Using Excedrin’s Nostalgic Game To Redefine Consumer Health Brand Moats?

Earlier this month, Excedrin, part of Haleon, launched Excedrin Rapid Relief, an aspirin-free and caffeine-free pain reliever featuring patented Fast Release Technology and promoted through “My Little Headache,” a nostalgic digital pet that illustrates escalating headache discomfort and the benefits of fast relief. The campaign’s playful but pointed use of interactive nostalgia to personify headache pain highlights how Haleon is experimenting with unconventional, engagement-led approaches to...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By